JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 23 No. 7 592-598
© 1982 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fritzberg, A. R.
Right arrow Articles by Whitney, W. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fritzberg, A. R.
Right arrow Articles by Whitney, W. P.

Synthesis and Biological Evaluation of Tc-99m N,N'-Bis(mercaptoacetyl)-2,3-diaminopropanoate: A Potential Replacement for [131I]o-iodohippurate

Alan R. Fritzberg, Christopher C. Kuni, W. C. Klingensmith, III, John Stevens and Wayne P. Whitney

University of Colorado Health Sciences Center and Veterans Administration Medical Center, Denver, Colorado

Correspondence: For reprints contact: Alan R. Fritzberg, PhD, Department of Radiology, A034, U. of Colorado Health Sciences Center, 4200 E. 9th Ave., Denver, CO 80262.

ABSTRACT

A new technetium-chelating agent based on amide and mercaptide donor groups, N,N'-bis(mercaptoacetyl)-2,3-diaminopropanoate, was synthesized as an analog of previously described N,N'-bis(mercaptoacetyl)ethylenediamine (DADS). Complexation of Tc-99m with the new chelating group resulted in two components that were separable by high-performance liquid chromatography. The component that eluted first demonstrated high specificity for renal excretion, with over 90% In the urine of rabbits at 35 min, 87% in the urine of mice at 2 hr, and 1.6% or less in the intestines of mice. Excretion was rapid, with the first component equaling or exceeding [131I]o-iodohippurate in the urine of rabbits at all times. The second or latter component demonstrated comparable specificity but slightly slower renal excretion kinetics. Clinical trials with the first component are probably warranted.




This article has been cited by other articles:


Home page
JNMHome page
M. Lipowska, H. He, E. Malveaux, X. Xu, L. G. Marzilli, and A. Taylor
First Evaluation of a 99mTc-Tricarbonyl Complex, 99mTc(CO)3(LAN), as a New Renal Radiopharmaceutical in Humans
J. Nucl. Med., June 1, 2006; 47(6): 1032 - 1040.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
A. T. Taylor, M. Lipowska, L. Hansen, E. Malveaux, and L. G. Marzilli
99mTc-MAEC Complexes: New Renal Radiopharmaceuticals Combining Characteristics of 99mTc-MAG3 and 99mTc-EC
J. Nucl. Med., May 1, 2004; 45(5): 885 - 891.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1982 by the Society of Nuclear Medicine.